Trial Profile
A Phase 1b, Multicenter, Open Label Study Evaluating Safety, Tolerability and Preliminary Efficacy of LiRIS 400 mg in Women With Ulcerative Interstitial Cystitis
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 16 May 2016
Price :
$35
*
At a glance
- Drugs Lidocaine (Primary)
- Indications Interstitial cystitis
- Focus Proof of concept; Therapeutic Use
- Sponsors Allergan; TARIS Biomedical
- 10 May 2016 Results of safety, tolerability and preliminary efficacy of LiRIS(R) 400 mg presented at the 111th Annual Meeting of the American Urological Association.
- 24 Nov 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 08 May 2014 Planned End Date changed from 1 Dec 2013 to 1 Dec 2014 as reported by ClinicalTrials.gov.